The MOTION study

Recruitment is now closed.

The MOTION study is exploring whether an investigational biologic drug can improve pain symptoms and limitations of joint function caused by knee osteoarthritis. 

The MOTION study is testing an investigational medication that could be used to treat painful knee osteoarthritis. This investigational biologic medication is an intra-articular (IA) injection (meaning – it’s injected inside the knee joint), and it may treat your OA pain, improve your knee joint function, and potentially delay the progression of your disease. 

What does the study aim to acheive?

Aim 1

To explore whether an investigational biologic drug can improve pain caused by knee osteoarthritis.

Aim 2

To explore whether an investigational biologic drug can improve limitations of joint function caused by knee osteoarthritis .

Who can take part?

The study is suitable for people who:

  • Are aged 40 – 80 years old 

  • Have experienced moderate to severe pain from osteoarthritis in only one of their knees for 6 months or longer 

The MOTION study FAQs

  • Recruitment is now closed.

  • This study consists of 3 parts:  

    1. Screening: You will undergo some initial assessments to see if the study is suitable for you. Depending on individual participant circumstances this may include 1 or 2 visits to finish all the assessments. This Screening period may last for up to 28 days.  

    2. Treatment: You will receive a single IA injection of the investigational product in your affected knee.  

    3. Follow-up Period: You will have regular follow-up assessments over a period of 12 months. The first 2 follow-up visits will be weekly, then will progress to visits every 3 months. 

  • If you agree to take part in this research study, and the research study is suitable for you, you will be in the study for up to 13 months. 

  • This research study will be conducted in a randomised, double-blind, placebo-controlled manner. This means that the participants will be divided randomly into two groups where half of the participants will receive investigational medication, and the other half will receive an inactive injection (referred to as a ‘placebo’) and neither yourself, nor the study doctor will know which you have received. 

If you have a question or would like further information about the study, please send an email to KOA-PTP.study@sydney.edu.au.